Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and risk of in situ breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
02 12 2019
Historique:
received: 18 07 2019
accepted: 08 10 2019
entrez: 3 12 2019
pubmed: 4 12 2019
medline: 24 4 2020
Statut: epublish

Résumé

Even though in situ breast cancer (BCIS) accounts for a large proportion of the breast cancers diagnosed, few studies have investigated potential risk factors for BCIS. Their results suggest that some established risk factors for invasive breast cancer have a similar impact on BCIS risk, but large population-based studies on lifestyle factors and BCIS risk are lacking. Thus, we investigated the association between lifestyle and BCIS risk within the European Prospective Investigation into Cancer and Nutrition cohort. Lifestyle was operationalized by a score reflecting the adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations. The recommendations utilized in these analyses were the ones pertinent to healthy body weight, physical activity, consumption of plant-based foods, energy-dense foods, red and processed meat, and sugary drinks and alcohol, as well as the recommendation on breastfeeding. Cox proportional hazards regression was used to assess the association between lifestyle score and BCIS risk. The results were presented as hazard ratios (HR) and corresponding 95% confidence intervals (CI). After an overall median follow-up time of 14.9 years, 1277 BCIS cases were diagnosed. Greater adherence to the WCRF/AICR cancer prevention recommendations was not associated with BCIS risk (HR = 0.98, 95% CI 0.93-1.03; per one unit of increase; multivariable model). An inverse association between the lifestyle score and BCIS risk was observed in study centers, where participants were recruited mainly via mammographic screening and attended additional screening throughout follow-up (HR = 0.85, 95% CI 0.73-0.99), but not in the remaining ones (HR = 0.99, 95% CI 0.94-1.05). While we did not observe an overall association between lifestyle and BCIS risk, our results indicate that lifestyle is associated with BCIS risk among women recruited via screening programs and with regular screening participation. This suggests that a true inverse association between lifestyle habits and BCIS risk in the overall cohort may have been masked by a lack of information on screening attendance. The potential inverse association between lifestyle and BCIS risk in our analyses is consistent with the inverse associations between lifestyle scores and breast cancer risk reported from previous studies.

Sections du résumé

BACKGROUND
Even though in situ breast cancer (BCIS) accounts for a large proportion of the breast cancers diagnosed, few studies have investigated potential risk factors for BCIS. Their results suggest that some established risk factors for invasive breast cancer have a similar impact on BCIS risk, but large population-based studies on lifestyle factors and BCIS risk are lacking. Thus, we investigated the association between lifestyle and BCIS risk within the European Prospective Investigation into Cancer and Nutrition cohort.
METHODS
Lifestyle was operationalized by a score reflecting the adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations. The recommendations utilized in these analyses were the ones pertinent to healthy body weight, physical activity, consumption of plant-based foods, energy-dense foods, red and processed meat, and sugary drinks and alcohol, as well as the recommendation on breastfeeding. Cox proportional hazards regression was used to assess the association between lifestyle score and BCIS risk. The results were presented as hazard ratios (HR) and corresponding 95% confidence intervals (CI).
RESULTS
After an overall median follow-up time of 14.9 years, 1277 BCIS cases were diagnosed. Greater adherence to the WCRF/AICR cancer prevention recommendations was not associated with BCIS risk (HR = 0.98, 95% CI 0.93-1.03; per one unit of increase; multivariable model). An inverse association between the lifestyle score and BCIS risk was observed in study centers, where participants were recruited mainly via mammographic screening and attended additional screening throughout follow-up (HR = 0.85, 95% CI 0.73-0.99), but not in the remaining ones (HR = 0.99, 95% CI 0.94-1.05).
CONCLUSIONS
While we did not observe an overall association between lifestyle and BCIS risk, our results indicate that lifestyle is associated with BCIS risk among women recruited via screening programs and with regular screening participation. This suggests that a true inverse association between lifestyle habits and BCIS risk in the overall cohort may have been masked by a lack of information on screening attendance. The potential inverse association between lifestyle and BCIS risk in our analyses is consistent with the inverse associations between lifestyle scores and breast cancer risk reported from previous studies.

Identifiants

pubmed: 31787099
doi: 10.1186/s12916-019-1444-0
pii: 10.1186/s12916-019-1444-0
pmc: PMC6886197
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

221

Subventions

Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A19170
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C570/A16491
Pays : United Kingdom

Références

Int J Cancer. 2006 Apr 1;118(7):1782-9
pubmed: 16231317
Int J Cancer. 2017 Jul 1;141(1):83-93
pubmed: 28380695
PLoS One. 2015 Jul 24;10(7):e0132684
pubmed: 26208331
Eur J Epidemiol. 2001;17(11):1047-53
pubmed: 12380720
Arch Intern Med. 2007 Feb 26;167(4):408-15
pubmed: 17325304
Am J Epidemiol. 2017 Dec 15;186(12):1329-1340
pubmed: 28637226
JAMA Oncol. 2018 Nov 1;4(11):e181771
pubmed: 29931120
CA Cancer J Clin. 2015 Nov-Dec;65(6):481-95
pubmed: 26431342
Eur J Clin Nutr. 2007 Sep;61(9):1037-56
pubmed: 17375121
Am J Public Health. 2010 Nov;100(11):2288-95
pubmed: 20864719
Breast Cancer Res. 2013 Jan 29;15(1):R9
pubmed: 23360535
Int J Cancer. 2012 Aug 15;131(4):930-7
pubmed: 21952983
J Natl Cancer Inst. 2004 Jun 16;96(12):906-20
pubmed: 15199110
Addiction. 2013 Dec;108(12):2051-7
pubmed: 23297738
Int J Cancer. 2014 Nov 15;135(10):2444-52
pubmed: 24723234
Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1498-508
pubmed: 23780838
Am J Clin Nutr. 2012 Jul;96(1):150-63
pubmed: 22592101
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
PLoS One. 2015 May 15;10(5):e0126096
pubmed: 25978407
Int J Epidemiol. 1997;26 Suppl 1:S6-14
pubmed: 9126529
Int J Cancer. 2017 Feb 15;140(4):764-776
pubmed: 27798951
Int J Epidemiol. 1997;26 Suppl 1:S15-25
pubmed: 9126530
Cancer Epidemiol Biomarkers Prev. 2012 Dec;21(12):2209-19
pubmed: 23074288
Public Health Nutr. 2015 Dec;18(18):3337-48
pubmed: 25805146
Br J Nutr. 2015 Jul 14;114(1):134-43
pubmed: 26051510
Int J Cancer. 2016 Jun 1;138(11):2602-15
pubmed: 26756307
Cancer Causes Control. 2015 Feb;26(2):277-286
pubmed: 25559553
Int J Cancer. 2016 Jun 1;138(11):2657-64
pubmed: 26804371

Auteurs

Nena Karavasiloglou (N)

Division of Chronic Disease Epidemiology, Institute for Epidemiology, Biostatistics and Prevention, University of Zurich, Zurich, Switzerland. nena.karavasiloglou@uzh.ch.
Cancer Registry Zurich and Zug, University Hospital Zurich, Zurich, Switzerland. nena.karavasiloglou@uzh.ch.
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. nena.karavasiloglou@uzh.ch.

Anika Hüsing (A)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Giovanna Masala (G)

Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy.

Carla H van Gils (CH)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Renée Turzanski Fortner (R)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Jenny Chang-Claude (J)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Inge Huybrechts (I)

International Agency for Research on Cancer, Lyon, France.

Elisabete Weiderpass (E)

International Agency for Research on Cancer, Lyon, France.
Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.

Marc Gunter (M)

International Agency for Research on Cancer, Lyon, France.

Patrick Arveux (P)

CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, 94805, Villejuif, France.
Gustave Roussy, F-94805, Villejuif, France.
Breast and Gynaecologic Cancer Registry of Côte d'Or, Georges-François Leclerc Cancer Centre, UNICANCER, Dijon, France.

Agnès Fournier (A)

CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, 94805, Villejuif, France.
Gustave Roussy, F-94805, Villejuif, France.

Marina Kvaskoff (M)

CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, 94805, Villejuif, France.
Gustave Roussy, F-94805, Villejuif, France.

Anne Tjønneland (A)

Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Danish Cancer Society Research Center, Copenhagen, Denmark.

Cecilie Kyrø (C)

Danish Cancer Society Research Center, Copenhagen, Denmark.

Christina C Dahm (CC)

Department of Public Health, Aarhus University, Aarhus, Denmark.

Helene Tilma Vistisen (HT)

Department of Public Health, Aarhus University, Aarhus, Denmark.

Marije F Bakker (MF)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Maria-Jose Sánchez (MJ)

Andalusian School of Public Health (EASP), Granada, Spain.
Instituto de Investigación Biosanitaria de Granada (ibs. GRANADA), Granada, Spain.
CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Universidad de Granada, Granada, Spain.

María Dolores Chirlaque López (MD)

CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
Department of Health and Social Sciences, Murcia University, Murcia, Spain.

Carmen Santiuste (C)

CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.

Eva Ardanaz (E)

CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Navarra Public Health Institute, Pamplona, Spain.
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.

Virginia Menéndez (V)

Public Health Directorate, Asturias, Spain.

Antonio Agudo (A)

Unit of Nutrition and Cancer, Catalan Institute of Oncology - ICO, Nutrition and Cancer Group, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Antonia Trichopoulou (A)

Hellenic Health Foundation, Athens, Greece.

Anna Karakatsani (A)

Hellenic Health Foundation, Athens, Greece.
2nd Pulmonary Medicine Department, School of Medicine, "ATTIKON" University Hospital, National and Kapodistrian University of Athens, Haidari, Greece.

Carlo La Vecchia (C)

Hellenic Health Foundation, Athens, Greece.
Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.

Eleni Peppa (E)

Hellenic Health Foundation, Athens, Greece.

Domenico Palli (D)

Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy.

Claudia Agnoli (C)

Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Salvatore Panico (S)

Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.

Rosario Tumino (R)

Cancer Registry and Histopathology Department, Azienda Sanitaria Provinciale (ASP), Ragusa, Italy.

Carlotta Sacerdote (C)

Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy.

Salma Tunå Butt (ST)

Department of Clinical Sciences, Lund University, Malmö, Sweden.
Department of Surgery, Skåne University Hospital, Malmö, Sweden.

Signe Borgquist (S)

Department of Oncology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark.
Division of Oncology and Pathology, Clinical Sciences, Lund University, Lund, Sweden.

Guri Skeie (G)

Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Nutritional Epidemiology Group, School of Food Science and Nutrition, University of Leeds, Leeds, UK.

Matthias Schulze (M)

Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.

Timothy Key (T)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Kay-Tee Khaw (KT)

Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Kostantinos K Tsilidis (KK)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.

Merete Ellingjord-Dale (M)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Elio Riboli (E)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Rudolf Kaaks (R)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Laure Dossus (L)

International Agency for Research on Cancer, Lyon, France.

Sabine Rohrmann (S)

Division of Chronic Disease Epidemiology, Institute for Epidemiology, Biostatistics and Prevention, University of Zurich, Zurich, Switzerland.
Cancer Registry Zurich and Zug, University Hospital Zurich, Zurich, Switzerland.

Tilman Kühn (T)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. t.kuehn@dkfz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH